CMPX

CMPX EBITDA Growth

-19.00%TTM

Period ending:

CMPX TTM EBITDA YoY %%
CMPX TTM EBITDA YoY %92.10%-257.16%
2020-09-302026-06-30

Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.

CMPX ebitda growth history

Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 24 observations from Sep 30, 2020 to Jun 30, 2026.

Compass Therapeutics EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
-18.9969%
-24.5067%
-36.5215%
-40.1943%
-33.2621%
-22.9436%
-17.2889%
-18.3919%
-13.0687%
-18.0717%
-11.9987%
-2.8221%
-24.1424%
53.8874%
54.7887%
49.3987%
58.297%
-195.1647%
-209.6899%
-200.3346%
-223.3586%
-45.6748%
-12.417%
-43.9371%

Compare ebitda growth

All CMPX financial metrics · CMPX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.